{"id":20406,"date":"2024-05-28T07:28:40","date_gmt":"2024-05-28T11:28:40","guid":{"rendered":"https:\/\/massivebio.com\/?p=20406"},"modified":"2025-09-24T10:39:38","modified_gmt":"2025-09-24T07:39:38","slug":"pcc-massive-bio-largest-ai-study-clinical-trial-match","status":"publish","type":"post","link":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/","title":{"rendered":"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study"},"content":{"rendered":"\r\n<p><style>\r\n@media only screen and (max-width: 768px) {\r\n.blog-hero .info-area .name {\r\n    margin: 15px 0 20px;\r\n    font-size: 32px;\r\n    font-weight: 500;\r\n    line-height: 45px;\r\n}    \r\n}\r\n<\/style><\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\"><strong>PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study<\/strong><\/h2>\r\n\r\n\r\n\r\n<p><strong>June 2024, ASCO Annual Meeting, Chicago<\/strong> \u2013 <a href=\"https:\/\/www.precisioncancerconsortium.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">The Precision Cancer Consortium (PCC<\/a>), in partnership with <a href=\"https:\/\/massivebio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Massive Bio<\/a>, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio&#8217;s existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform. The consortium includes top pharmaceutical giants such as AstraZeneca, Bayer, Eli Lilly &amp; Company, GSK, Johnson &amp; Johnson, Novartis, and Roche.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\">Background<\/h2>\r\n\r\n\r\n\r\n<p>Manual screening of patients for cancer trials is traditionally a resource-intensive process, taking about 25 minutes per trial and limiting patient access to suitable trials. This not only restricts available trial options but also adversely impacts enrollment rates. In response, Massive Bio and the PCC implemented an advanced multi-trial matching method that integrates Next-Generation Sequencing (NGS) results and utilizes AI to enhance both the accuracy and efficiency of trial matching, particularly for targeted therapies.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\">Methods<\/h2>\r\n\r\n\r\n\r\n<p>Massive Bio\u2019s established AI system uses computer vision and natural language processing to extract 180 structured clinical parameters from medical records, and has been optimized using GPT-4 Large Language Model (LLM) and fine-tuned for the oncology and biomarker-specific use case. This system matches patients to digitized inclusion\/exclusion criteria of more than 14,000 actively recruiting interventional cancer trials, using an AI-driven recommendation algorithm.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\">Key Findings<\/h2>\r\n\r\n\r\n\r\n<p><strong>\u2022 Patient Data Analysis:<\/strong> From a dataset of 5,707 cancer patients, only 1,557 (27%) had accessible NGS testing results.<\/p>\r\n\r\n\r\n\r\n<p><strong>\u2022 Trial Matching Improvements:<\/strong> The study matched 690 unique patients to at least one trial, creating 1,254 patient-trial pairs\u2014a 1.82-fold increase due to the multi-trial matching approach.<\/p>\r\n\r\n\r\n\r\n<p><strong>\u2022 Potential Increase with Full NGS:<\/strong> Assuming full NGS testing availability, the study projected 2,635 matching pairs, indicating a potential 2.1-fold increase.<\/p>\r\n\r\n\r\n\r\n<p><strong>\u2022 Targeted Therapy Case Study:<\/strong> In lung cancer trials focusing on the EGFR gene, matching surged to a 12.4-fold increase for unique patients.<\/p>\r\n\r\n\r\n\r\n<p><strong>\u2022 Matching Efficiency:<\/strong> The system matched or exceeded theoretical rates in 80% of trials, significantly reducing manual effort with an estimated savings of 19,500 hours (nearly 100% efficiency).<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\"><strong>Conclusion<\/strong><\/h2>\r\n\r\n\r\n\r\n<p>The fusion of NGS and AI in a multi-trial matching framework has not only nearly doubled the potential eligibility for patients across various tumor types but also achieved a twelve-fold increase in matching efficiency for specific tumor profiles, significantly curtailing manual labor.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\"><strong>Future Directions<\/strong><\/h2>\r\n\r\n\r\n\r\n<p>Further nationwide analysis is under consideration to expand upon these promising results.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\"><strong>Reference:<\/strong><\/h2>\r\n\r\n\r\n\r\n<p>Kurnaz S, Loaiza-Bonilla A, Carvallo Castaneda D, Huner O. Effect of a novel artificial intelligence (AI) \u2013enabled multi-trial matching system on patient matching using real-world data. J Clin Oncol 42, 2024 (suppl 16; abstr e13501). 2024 ASCO Annual Meeting.<\/p>\r\n\r\n\r\n\r\n<h2 style=\"font-size: 18px; line-height: 28px;\"><strong>About the Precision Cancer Consortium (PCC)<\/strong><\/h2>\r\n\r\n\r\n\r\n<p>The Precision Cancer Consortium comprises pharmaceutical and biotechnology companies dedicated to advancing precision oncology to improve patient outcomes by increasing access to comprehensive genomic testing and addressing precision diagnostics gaps. For more information, visit Precision Cancer Consortium.<\/p>\r\n\r\n\r\n\r\n<p>Precision Cancer Consortium<br \/><strong>Email:<\/strong> <a href=\"mailto:pccadmin@precisioncancerconsortium.com\" target=\"_blank\" rel=\"noreferrer noopener\">pccadmin@precisioncancerconsortium.com<\/a><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study June 2024, ASCO Annual Meeting, Chicago \u2013 The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio&#8217;s existing&#8230;<\/p>\n","protected":false},"author":11,"featured_media":20725,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-20406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Massive Bio Unveils Groundbreaking Oncology\/Hematology AI Platform at ASCO 2024: Revolutionizing Oncology\/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility<\/title>\n<meta name=\"description\" content=\"Massive Bio unveils groundbreaking ai-driven personalized platform in oncology\/hematology at ASCO 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study %\" \/>\n<meta property=\"og:description\" content=\"Massive Bio unveils groundbreaking ai-driven personalized platform in oncology\/hematology at ASCO 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-28T11:28:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-24T07:39:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"576\" \/>\n\t<meta property=\"og:image:height\" content=\"432\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Massive Bio Unveils Groundbreaking Oncology\/Hematology AI Platform at ASCO 2024: Revolutionizing Oncology\/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility","description":"Massive Bio unveils groundbreaking ai-driven personalized platform in oncology\/hematology at ASCO 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/","og_locale":"en_US","og_type":"article","og_title":"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study %","og_description":"Massive Bio unveils groundbreaking ai-driven personalized platform in oncology\/hematology at ASCO 2024.","og_url":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2024-05-28T11:28:40+00:00","article_modified_time":"2025-09-24T07:39:38+00:00","og_image":[{"width":576,"height":432,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study","datePublished":"2024-05-28T11:28:40+00:00","dateModified":"2025-09-24T07:39:38+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/"},"wordCount":504,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/","url":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/","name":"Massive Bio Unveils Groundbreaking Oncology\/Hematology AI Platform at ASCO 2024: Revolutionizing Oncology\/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp","datePublished":"2024-05-28T11:28:40+00:00","dateModified":"2025-09-24T07:39:38+00:00","description":"Massive Bio unveils groundbreaking ai-driven personalized platform in oncology\/hematology at ASCO 2024.","breadcrumb":{"@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/05\/pcc-mobil-pcc.webp","width":576,"height":432,"caption":"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/pcc-massive-bio-largest-ai-study-clinical-trial-match\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/massivebio.com\/resources\/news-en\/"},{"@type":"ListItem","position":3,"name":"PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists &amp; Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/20406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=20406"}],"version-history":[{"count":1,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/20406\/revisions"}],"predecessor-version":[{"id":35562,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/20406\/revisions\/35562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/20725"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=20406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=20406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=20406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}